Accessibility Menu
Xtl Biopharmaceuticals logo

Xtl Biopharmaceuticals(NASDAQ) XTLB

Market Cap$6.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-79%
1 Year-49%
1 Month+6%
$2.80
-0.71%
-0.02Today
Xtl Biopharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 2.862026-08-03
Xtl Biopharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.67%USD 2.882026-07-27
1 month+5.96%USD 2.702026-07-02
3 month-21.84%USD 3.662026-05-05
Year to date+23.31%USD 2.322025-12-31
1 year-48.55%USD 5.562025-08-01
3 year-8.32%USD 3.122023-08-04
5 year-79.15%USD 13.722021-08-04
Since inception-99.87%USD 2,284.002005-09-01

Xtl Biopharmaceuticals Financials at a Glance

Market Cap

$6.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$451.00K

Net Income (TTM)

-$1.03M

EPS (TTM)

$0.00

P/E Ratio

-6.39

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$2.80

Volume

9,178.024

Open

$2.69

Previous Close

$2.86

Daily Range

$2.60 - $2.96

52-Week Range

$2.01 - $10.28

Estimated Earnings Date

Apr 29, 2026

XTLB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Xtl Biopharmaceuticals

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm focused on developing innovative drug therapies for autoimmune diseases. The company's lead investigational compound, hCDR1, is set to enter Phase II trials targeting systemic lupus erythematosus and Sjogren's syndrome.

Products and Services
  • hCDR1, an investigational drug for autoimmune conditions
  • Licensing agreement with Yeda Research for drug development
  • Focus on multiple therapeutic indications for hCDR1
Growth Outlook
  • hCDR1's Phase II trials could significantly enhance market presence
  • Strong licensing agreement supports research and commercialization efforts
  • Potential expansion into additional therapeutic areas beyond current focus
Financial Highlights
  • Recent quarterly revenue of $289,000 shows growth potential
  • Cash and short-term investments reached $1.14 million in Q4 2024
  • Net income improved to -$255,000 in Q4 2024 from -$553,000 in Q3 2024
XTL Biopharmaceuticals Ltd. operates in the biotechnology sector, with a strategic focus on autoimmune diseases. The company has a promising pipeline, particularly with hCDR1, which is anticipated to enter critical trial phases. The licensing agreement with Yeda Research enhances the company's ability to advance its drug development initiatives. Recent financial data indicates a positive trajectory, with increasing revenue and improving net income figures, suggesting a potential turnaround. The company's financial position, bolstered by cash reserves, provides a foundation for future growth and development in the biopharmaceutical landscape.
AI Generated • Jul 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

Shlomo Spokone Shalev, MBA

Website

www.xtlbio.com

Headquarters

Ramat Gan, TA 5218102, IL

XTLB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-269.02%

Return on Capital

-11253.33%

Return on Assets

-4198.19%

Earnings Yield

-15.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.37M

Volume

9.18K

Avg. Volume

88.21K

Financials (TTM)

Gross Profit

$119.00K

Operating Income

-$2.17M

EBITDA

-$791.25K

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$144.00K

Total Debt

$269.00K

Xtl Biopharmaceuticals Performance Analysis

Xtl Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Xtl Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-3178.4%
Q42025-12-31N/A
Xtl Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.98N/A
20232023-12-31USD -1.3032.6%
20242024-12-31USD -0.61-52.9%
20252025-12-31USD -0.34-44.3%
Xtl Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-244.4%
Q32024-09-3023.1%
Q42024-12-3160.0%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$289.00K

N/A

Gross Profit

-$43.00K

N/A

Gross Margin

-14.88%

N/A

Market Cap

$6.77MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$676.75K

N/A

Employees

10

N/A

Net Income

-$255.00K

+10.2%

EBITDA

-$429.25K

-51.1%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$144.00K

-93.8%

Total Debt

$269.00K

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$269.00K

N/A

Return on Assets

-41.98%

N/A

Return on Invested Capital

6.65%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TCRTAlaunos Therapeutics, Inc.
$1.92+0.79%
QNRXQuoin Pharmaceuticals, Ltd.
$4.46+0.22%
RADXRadiopharm Theranostics Limited
$3.09-0.64%
ENSCEnsysce Biosciences, Inc.
$0.39+40.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.92+0.30%
AMIXAutonomix Medical
$17.27+3.73%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.03+0.03%
NOKNokia
$10.04+0.07%

Questions About XTLB

What is the current price of Xtl Biopharmaceuticals?

Xtl Biopharmaceuticals is trading at $2.96 per share.

What is the 52-week range for Xtl Biopharmaceuticals?

Over the past 52 weeks, Xtl Biopharmaceuticals has traded between $2.01 and $10.28.

How much debt does Xtl Biopharmaceuticals have?

As of the most recent reporting period, Xtl Biopharmaceuticals reported total debt of $138.00K.

How much cash does Xtl Biopharmaceuticals have on hand?

Xtl Biopharmaceuticals reported $371.00K in cash and cash equivalents in its most recent financial results.

What is Xtl Biopharmaceuticals’s dividend yield?

Xtl Biopharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services